Medical unicorn zero-yuan technology completed 700 million yuan of D-plus round of financing, comprehensively accelerate the serious illness "medical-drug-risk" commercial closed-loop landing.

Introduction: Zero-sein technology to further focus on the financing of new special drugs for tumors.
September 2020, China's medical big data unicorn company LinkDocTechnology completed a 700 million yuan round of financing for D-plus.
this round of new investors includes ZHONGKIN, Youshan Capital, Jinnanhai River Broadband Zhihui Industry Fund and so on.
investors continue to follow suit.
After this round of financing, zero-sorm technology will further focus on the core business development of the new cancer specialty drug "T3D", establish a patient service system covering the patient's whole disease treatment cycle, Internet hospitals, offline professional clinic pharmacies, and clinical recruitment of new drugs as the core, establish a real-world data platform for the development of new cancer drugs, establish an innovative insurance payment plan oriented by value medicine and supported by medical evidence, and ultimately build a medical technology solution for China's medical industry.
Zero is committed to working with all parties in the industry to accelerate the digitalization process of China's biopharmaceutical industry, promote the development of medical, pharmaceutical and insurance business models in the field of serious diseases, promote new infrastructure construction such as big data and artificial intelligence, support socio-economic development and benefit the public.
.